CRN Says GSK Swings Wide Against Alli Competition With Weight-Loss Petition
This article was originally published in The Tan Sheet
The Council for Responsible Nutrition says GlaxoSmithKline's request that FDA reclassify weight-loss claims as disease claims would essentially eliminate nonprescription competition for GSK's OTC drug alli and "cripple the dietary supplement category.
You may also be interested in...
The Electronic Retailing Self-Regulation Program referred advertising for NVE Pharmaceuticals' AppuLoss dietary supplement to the Federal Trade Commission after the firm failed to respond to an inquiry
Manufacturers would need pre-market approval to make weight-loss claims for supplements if FDA implements a rulemaking recommended by petitioners, including GlaxoSmithKline, the manufacturer of OTC weight-loss drug alli.
CRN is committing nearly half a million dollars over a three year period to triple the annual number of dietary supplement cases reviewed by the Council of Better Business Bureaus' National Advertising Division (NAD)